Hikma Pharmaceuticals PLC, the fast growing multinational pharmaceutical group, today announces the approval of its New Drug Application for colchicine 0.6 mg capsules by the US Food and Drug Administration. Hikma will market its colchicine under the brand name MITIGARE. Said Darwazah, Chairman and CEO of Hikma, said, "This approval demonstrates ou
By a News Reporter-Staff News Editor at Biotech Week Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced new pre-clinical results with ALN-CC5, a subcutaneously administered RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases. These results were presented at
From June 2011 until February 2014, Dr. Wierenga served as Executive Vice President, Research and Development of Santarus, Inc., a public biopharmaceutical company that was acquired by Salix Pharmaceuticals, Ltd. in January 2014. From 2003 to 2007, Dr. Wierenga served as Executive Vice President, Research and Development of Neurocrine Biosciences,
Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced positive results from its 371 patient Phase 2 b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome. "We are pleased to see that tenapanor continues to...
By a News Reporter-Staff News Editor at Biotech Week Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced the first presentation of positive safety and efficacy data from the AUX-CC-867 MULTICORD Phase 3 b study. These data will be presented at the 69 Annual Meeting of the American Society for Surgery of the Hand being
By a News Reporter-Staff News Editor at Biotech Week Avanir Pharmaceuticals, Inc. announced positive results from its phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease. "This is an exciting advancement in Alzheimer's disease research," said Jeffrey Cummings,
Boston Therapeutics, Inc., a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Jan Brinkman, M.D., Ph.D. and Alan M. Hoberman, Ph.D. to its Board of Directors, effective immediately. Dr. Brinkman has served as a member of the Biotechnology Business Strategies Committee with ABN-Amro Bank N.V.
Celladon Corporation, a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held Octob
Dr. Hobden's esteemed career includes as President of Myriad Pharmaceuticals, a wholly owned subsidiary of Myriad Genetics, which he founded in 1998 and grew into an integrated R %7 ED organization of 220 employees with responsibility to manage the largest placebo controlled trial of an experimental Alzheimer medicine that had ever been run.
In the world of mobile technology we have an app for everything, but mission-critical information about the clinical trials that physicians are managing seems to be in the prehistoric days. Clinical trials have inherently become more complex over the years, especially with infectious disease, cardiovascular, oncology and CNS trials. The number of
Conatus Pharmaceuticals Inc., a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the appointment of David T. Hagerty, M.D., as Executive Vice President, Clinical Development, with oversight responsibility for the company's medical activities including Clinical...
Tianhe is performing Phase I/II clinical trials in China and Spain using Tianhe's Stem Cell Educator Therapy showing that the therapy is safe. Yong Zhao, President of Tianhe. x0D;. This partnership signifies our commitment to this mission and to the cutting edge research and clinical trials necessary to provide new therapies that could benefit la
By a News Reporter-Staff News Editor at Biotech Week CSL Behring announced that the last patient has been treated as part of the REPLACE Phase III clinical trial. Niels Rahe-Meyer, Professor and Head of the Department of Anesthesiology and Intensive Care, Franziskus Hospital, Bielefeld, Germany and coordinating investigator of the study.
By a News Reporter-Staff News Editor at Biotech Week Eli Lilly and Company announced that results of the global Phase III trial of ramucirumab in combination with paclitaxel in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma were published in the online version of The Lancet Oncology. Data from the RAINBOW trial
Data on Clinical Trials and Studies Discussed by Researchers at Central Hospital. According to news reporting out of Chongqing, People's Republic of China, by NewsRx editors, research stated, "To investigate the effects of oxytocin on high-intensity focused ultrasound ablation for the treatment of adenomyosis. Our news journalists obtained a quote
DGAP-News: ERYTECH PHARMA SA/ Key word: Study results ERYTECH reports positive top-line Phase III results from clinical study with GRASPA (R) in Acute Lymphoblastic Leukemia 01.10. 2014/ 09:30- ERYTECH reports positive top-line Phase III results from clinical study with GRASPA (R)
Is it really possible to reverse the aging process, to look younger and to feel better? A Diet Doc in-house clinical study revealed that thousands of patients affirm that prescription Sermorelin hGH anti-aging therapy has enabled them to look younger and feel better with revitalized energy, improved sleep quality and improved memory and mood.
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that 25 abstracts reporting the results of hepatitis C virus treatment regimens containing ABT-450, Enanta s lead protease inhibitor, or ABT-493, Enanta s next-gener
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that the company has entered into an agreement to regain full rights from Novartis to EDP-239, an NS5A inhibitor currently in phase 1 development for hepatitis C virus.
Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced, in conjunction with its development partner Eisai, that clinical data from the ongoing Phase 1 study of EPZ-6438, an oral, small molecule inhibitor of EZH2, will be featured in a...
Esperion Therapeutics, Inc., an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced positive top-line results from ETC-1002-008, a Phase 2 b study...
By a News Reporter-Staff News Editor at Biotech Week Baxter International Inc. announced that the United States Food and Drug Administration has approved RIXUBIS for routine prophylactic treatment, control and prevention of bleeding episodes, and perioperative management in children with hemophilia B. RIXUBIS was the first recombinant factor IX..
SUMMARY: The Food and Drug Administration is announcing the fee rate for using a rare pediatric disease priority review voucher for fiscal year 2015. The Federal Food, Drug, and Cosmetic Act, as amended by the Food and Drug Administration Safety and Innovation Act, authorizes FDA to determine and collect rare pediatric disease priority review user
DNA Vaccine pioneer Immunomic Therapeutics, Inc., a privately held biotechnology company, submitted a new Investigational New Drug Application to the FDA on September 10th. ITI plans to use the results from this study, which will take place in Japan, to support future clinical studies in the United States. As a result of submitting IND for the Phas
Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company's abstract titled "Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis with advanced fibrosis" was accepted as an oral